Bioassay of safinamide in biological fluids of humans and various animal species.
This paper describes three methods to bioassay safinamide (CAS 133865-89-1) in biological fluids of humans and laboratory animals for pharmacokinetic, toxicokinetic and bioavailability studies. Two methods profited from liquid chromatography tandem mass spectrometry (LC-MS-MS) system, one (micro bioassay) working in the low dynamic range 0.5-20 ng/ml, the other in the range 20-6000 ng/ml. A third method used high-performance liquid chromatrography with fluorimetric detection (HPLC-FD), working in the dynamic range 20-1000 ng/ml. All the three methods were validated in compliance with the accreditated views on analytical bioassays. The shorter run time (5.5 min vs 16 min) has led the authors to prefer the two LC-MS-MS methods to the HPLC-FD bioassay, even if all the performances of the three methods were excellent. The methods described in this paper were and are still now extensively used to assay safinamide in more than 10,000 specimens of biological fluids from humans and laboratory animals in the development program of the drug. Main pharmacokinetic results obtained in various Phase I trials on healthy volunteers are briefly reported.